CRL Stock Recent News

Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Integration of Akadeum's GMP-grade Human T Cell Leukopak Isolation Kit into Charles River's Cell Therapy Flex Program announced today.

CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .

Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.

Charles River Laboratories International Inc. CRL stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expected to decline sequentially.

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.